Category: Medical innovation

Globally, bacterial antimicrobial resistance was directly responsible for an estimated 1.27 million deaths in 2019, a figure projected to rise dramatically [1.9.1, 1.9.4]. This crisis fuels the need for novel therapeutic strategies, leading to the development of advanced systems that ask, **What is Trojan medication?** and how can it overcome these challenges.

In 2024, the FDA approved Casgevy, the first CRISPR-based gene therapy for sickle cell disease, demonstrating how a foundational scientific discovery can become a drug that opens the doors to a new drug, validating a new modality of medicine entirely. This landmark approval was the culmination of decades of research and has fundamentally shifted the paradigm for treating genetic disorders.